Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,758 total articles
LifeVantage Corporation, a leader in health and wellness products rooted in nutrigenomics, announced that it will release its fourth quarter and full fiscal year 2026 financial results on August 27, 2026. An investor conference call and webcast will follow the release to discuss the company's performance and outlook.
CaliberCos Inc. reported second quarter 2026 financial results showing Platform Adjusted EBITDA turning positive at $0.3 million, indicating progress towards profitability. Despite a decline in platform revenue to $3.7 million, the company reaffirmed full-year 2026 guidance and highlighted major milestones including the groundbreaking of its Steamb…
Calidi Biotherapeutics announced its second quarter 2026 financial results, highlighting positive FDA pre-IND feedback on its lead candidate CLD-401, progress in its RedTail oncolytic virus platform, presentation of preclinical data for CLD-501 at ASCO 2026, board expansion with industry veteran Corsee Sanders, and a 48% reduction in general and ad…
Tempest Therapeutics announced its Q2 2026 financial results and strategic business updates, highlighting the advancement of its next-generation in vivo CAR-T platform including collaboration with Senlang Biotechnology for TPST-4003, anticipates initial clinical data in H1 2027, positive interim clinical data for TPST-2003, and corporate developmen…
CPI Aerostructures, Inc. reported substantial year-over-year improvement for Q2 and the first six months of 2026, highlighted by increased revenues, higher gross margins, and positive net income compared to losses in the prior year periods. Revenue for Q2 rose to $17.6 million from $15.2 million, with net income turning positive at $0.7 million ver…
Genelux Corporation, a clinical-stage immuno-oncology company, announced its second quarter 2026 financial results showing a net loss of $9.5 million and $18.7 million in cash reserves expected to fund operations into early 2027. The company is progressing its Olvi-Vec immunotherapy clinical trials in platinum-resistant ovarian cancer and lung canc…
Oportun has appointed Scott Scheirman to its Board of Directors, where he will chair the Audit & Risk Committee and join the Compensation & Leadership Committee. With extensive leadership experience from companies like CPI Card Group, Western Union, and Fiserv, Scheirman is expected to enhance Oportun's strategic planning and execution to support p…
Actelis Networks, Inc. reported a 20% year-over-year increase in second quarter 2026 revenues to $1.1 million with gross margins improving to 51%. The company expanded market presence across Intelligent Transportation Systems, U.S. carriers, and multi-dwelling unit markets while implementing cost reductions and operational efficiencies. Actelis is …
KULR Technology Group announced its second quarter 2026 financial results, revealing a 43% revenue decline and a significant net loss of $21.97 million, primarily due to a non-cash $10.6 million fair value loss from its bitcoin holdings. The company is refocusing on its core energy platform, exiting bitcoin mining, repaying related debt, and reduci…
Edesa Biotech announced fiscal Q3 2026 results, highlighting readiness for its Phase 2 clinical trial of EB06 for vitiligo and positive exploratory analyses of paridiprubart in ARDS patients with acute kidney injury. The company is progressing in clinical execution and engaging strategic discussions for paridiprubart's late-stage development and co…
Burlington Stores, a leading off-price retailer, will release its Q2 fiscal year 2026 earnings before the U.S. market opens on August 27, 2026. The company will host a conference call and webcast to discuss results. Burlington operates over 1,200 stores nationwide and offers branded apparel and home merchandise at discounted prices.
Akari Therapeutics reported robust Q2 2026 financials highlighted by $8.6 million in financing and progression of its lead antibody drug conjugate candidate, AKTX-101, towards a planned Phase 1 clinical trial in mid-2027. The company showcased compelling ASCO 2026 preclinical data demonstrating synergistic anti-tumor activity in KRAS-mutated pancre…
Cadrenal Therapeutics reported a net loss of $3.3 million for Q2 2026, with decreased operating expenses compared to the prior year period. The company highlighted significant clinical advances, including promising Phase 2 data for CAD-1005 reducing thrombotic events by over 25%. Cadrenal launched a strategic partnering process for its Cardiac Acut…
Innventure, Inc. reported its second quarter 2026 financial results, highlighting ongoing belief in long-term demand for two-phase liquid cooling technology driven by AI infrastructure growth. The company announced it is suspending prior 2026 revenue and cash flow targets for its Accelsius subsidiary due to changing market conditions impacting near…
Profound Medical Corp. announced the launch of 'Let's Huddle,' a global patient community aimed at supporting men diagnosed with prostate disease by providing education, peer connection, advocacy, and shared experiences throughout diagnosis, treatment, and survivorship. The initiative enhances patient-centered care alongside Profound's innovative M…
Blaize Holdings, Inc. reported Q2 2026 revenue of $12.0 million, a significant sequential increase from Q1, driven by activity in its AI computing platforms. However, the company revised its full-year revenue guidance down to $40 to $43 million due to slower order conversion and increased memory costs. Blaize secured a large server order worth appr…
Tri Pointe Homes, Inc. announced its second quarter 2026 results showing a 22.1% decline in home sales revenue to $685.1 million and a 23.6% drop in new home deliveries compared to the prior year. The quarter included significant charges related to the Sumitomo Forestry transaction totaling $196.8 million and inventory impairment charges. Adjusted …
Serina Therapeutics completed enrollment and dosing for Cohort 1 of its Phase 1b registrational study of SER-252 ahead of schedule. The single-ascending-dose data top line results are expected in the first half of 2027. The company also announced a development partnership with Gannet BioChem for manufacturing support and appointed Farrell Simon, Ph…
Lianhe Sowell International Group Ltd announced its fiscal year 2026 financial results, reporting an 18% increase in total revenues to $43.27 million driven by 40% growth in electronic products. Despite top-line growth, the company posted a net loss of $5.65 million due to a 148% surge in operating expenses fueled by strategic investments in R&D an…
Martin Marietta Materials, Inc. has increased its quarterly cash dividend from $0.83 to $0.84 per share, marking its eleventh consecutive annual dividend raise. The dividend is payable on September 30, 2026, to shareholders of record as of September 1, 2026. The company highlights its strong cash flow, durable business model, and confidence in sust…
AmpliTech Group, a US-based manufacturer of advanced RF and microwave components, announced Q2 2026 revenue of $8.07 million, up 50.9% sequentially, with gross profit increasing 161.2% YoY. The company invested heavily in R&D, especially in 5G and MMIC technologies, and strengthened its balance sheet with a successful Series A rights offering. It c…
Elutia Inc. announced securing up to $26 million in funding to support the FDA clearance and full commercial launch of its antibiotic-eluting biomatrix product, NXT-41x, without issuing new equity. The company reported Q2 2026 financials showing a net loss of $7.6 million but progresses on regulatory and manufacturing milestones with strong surgeon…
Xos, Inc. reported significant improvements in its first-half 2026 financials, expanding GAAP gross margin from 11.8% to 31.0% and non-GAAP gross margin from 4.9% to 29.0% year-over-year. The company reduced operating expenses by 8.6%, narrowed operating losses substantially, and improved EBITDA metrics while launching the new Power Hub energy stor…
Celcuity Inc. reported second quarter 2026 financial results and corporate updates highlighting the FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- PIK3CA wild-type advanced breast cancer, with commercial launch expected in Q3 2026. The company also announced positive Phase 3 VIKTORIA-1 trial results in the PIK3CA mutant cohort, supporting a …
Midera Food Processing, newly independent from The Middleby Corporation as of July 2026, reported a 13.2% increase in net sales to $245 million in Q2 2026 alongside a 16% increase in orders and a record backlog of $446 million. Despite a decline in net earnings compared to the prior year, the company posted a 10.6% increase in estimated standalone …
